Huadong Medicine's (SHE:000963) unit, Zhejiang Doer Biologics, has received clinical trial approval from China's National Medical Products Administration for DR30206 for injection, according to a Tuesday filing on the Shenzhen bourse.
The drug will be evaluated as a treatment for patients with recurrent or metastatic head and neck squamous cell carcinoma in combination with chemotherapy.
The Chinese drugmaker's shares fell over 1% Tuesday morning in Shenzhen.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments